

# Pre- and Post-Exposure Options for CLL Patients

## COVID-19 Omicron Variant

Jim Werner

Volunteer Facilitator

NE Ohio CLL Support Group

January 25, 2022




# Pre-Exposure Prophylaxis for Omicron Variant

- Mask wearing (N95), physical distancing, hand washing, disinfecting surfaces, avoiding poorly ventilated spaces & crowds, testing as needed
- Manage any other chronic health conditions to reduce risk of poor outcomes
- General Population: 2 vaccine doses plus 3<sup>rd</sup> booster dose
  - Provides protection against Omicron variant
  - Vaccine induced T cells work against Omicron, vaccine induced B cells adapt & target variants
  - Breakthrough infections occur in healthy vaccinated adults
  - 3<sup>rd</sup> shot (booster) significantly improves protection
  - Clearly protective against severe illness, hospitalization and death
- CLL patients: 4<sup>th</sup> vaccine dose now recommended
  - CDC:
    - Primary doses: shots 1 & 2
    - Additional primary dose: shot 3
      - Booster: shot 4
    - To be given 5 months after the 3<sup>rd</sup> dose
  - CDC not recommending 'mixing and matching' Moderna & Pfizer vaccines in immunocompromised individuals



# Pre-Exposure Prophylaxis for Omicron Variant

- Evusheld (EUA) (IM)
  - Monoclonal antibodies (combination of two)
  - Active against Omicron variant
  - PREP: Only for pre-exposure, not for post-exposure
  - For people with moderate to severely compromised immune systems or severe adverse reactions to Covid vaccines
  - PROVENT trial: participants unvaccinated & at increased risk for poor outcomes (eg, over age 60, comorbidities)
    - Confirmed infections in 8 of 3441 (0.2%) in the Evusheld arm and in 17 of 1731 (1.0%) in the placebo arm
    - 77% reduction in the incidence of RT-PCR-confirmed symptomatic infection
  - Provides an added measure of protection against Covid for up to 6 months
  - Two intramuscular injections given during the same visit




# Pre-Exposure Prophylaxis for Omicron Variant

- Evusheld (EUA) (IM) (continued)
  - In short supply
  - Tiered system of distribution
    - Check therapeutic locator database (<https://healthdata.gov/Health/COVID-19-Public-Therapeutic-Locator/rxn6-qnx8/data>)
      - Doses available (Cleveland) CCF: 1242; UH: --; MetroHealth: --
- Implications for CLL patients returning to more normal lifestyles -- ???

# Post-Exposure Treatment of Omicron Variant

## Monoclonal Antibodies

- Xevudy (Sotrovimab) (IV) EUA
  - Active against Omicron variant, but not BA.2
  - For those with high risk of progression to severe Covid
  - Administer as soon as possible after positive viral test and within 7 days of symptom onset where BA.2 is not the dominant strain
  - 79% reduction in hospitalizations
  - 74% reduction in respiratory complications
  - In short supply
- Regen-Cov and "Bam-Ete"
  - Offer little or no protection against Omicron variant
  - EUA revised, no longer recommended
- Bebtelovimab (IV) EUA
  - Works for all variants including BA.2
  - In short supply



# Convalescent Plasma

## Plasma (& antibodies) from Recovered Covid Patients




- NIH Covid-19 Treatment Guidelines, Dec. 2021
  - “There is physiologic rationale for the value of convalescent plasma in immunocompromised people...”
  - “Although some reports suggest benefit, there are no definitive data to support the use of convalescent plasma in immunocompromised patients)... there is insufficient evidence for the Panel to recommend either for or against the use of COVID-19 convalescent plasma in this population (immunocompromised patients).”
- Discuss with your doctor as it is rarely used now since the authorization of the anti-SARS-COV-2 antibodies.

# Post-Exposure Treatment of Omicron Variant

## Antiviral Medication

- Paxlovid (nirmatrelvir plus ritonavir; capsule) EUA
  - Active against Omicron
- To prevent progression in high-risk patients with mild to moderate Covid-19
- 89% effective in preventing progression to severe Covid
- Take within 5 days of symptom onset
- Potentially dangerous CLL drug interactions (BTK inhibitors, BCL-2 inhibitors)
  - Consult with your CLL hem/onc first
- Therapeutic locator: (Cleveland) Doses available: CCF: 216; UH: --; MetroHealth: 30



CLL Society video on Paxlovid/CLL drug interactions: <https://cllsociety.org/2022/01/covid-19-dr-sameer-parikh-on-drug-interactions-between-paxlovid-and-cll-sll-drugs/>

# Post-Exposure Treatment of Omicron Variant

## Antiviral Medication

- Veklury (remdesivir; IV administration) EUA
  - Active against Omicron
  - 87% effective in preventing progression to severe Covid
  - Start within a few days of symptom onset
  - Initially for hospitalized patients at high risk for progression to severe Covid
  - Now also approved for non-hospitalized patients at high risk for progression to severe Covid
    - Treatment earlier in disease progression shows better results
- Not in Therapeutic Locator database for Cleveland
  - Likely to be adequate supply



# Post-Exposure Treatment of Omicron Variant

## Antiviral Medication

- Lagevrio (molnupiravir; capsule) EUA
  - Active against Omicron
  - For adults with mild to moderate Covid who are at high risk for progression to severe Covid
  - 30-50% effective in preventing progression to severe Covid
  - Start within 5 days of symptom onset
  - Activity can be boosted by supplementing with Paxlovid; synergistic effect
- Therapeutic Locator (Cleveland): Doses available: CCF: 1588; UH: --; MetroHealth: 40



# Summary



**Many great tools and options developed in less than 24 months!**

## **To prevent Covid infection:**

- Continue mask wearing, physical distancing, handwashing, hygiene measures, etc.
- Obtain 3 doses of vaccine plus 4<sup>th</sup> dose (booster) -- recommended at OSU
  - Unless otherwise advised by your doctor
- Obtain Evusheld pre-exposure prophylaxis
  - CLL patients are likely to be given high priority
  - Contact your doctors (hem/onc, PCP) now about this now
    - CLL Society's Official Triage Statement to providers

# Summary (continued)

- **If you test positive for Covid**
  - Contact your doctors (hem/oncs, PCP) right away
    - CLL Society's Official Triage Statement to providers
  - Small hospitals may not have as many treatment options or experience with Covid treatment for CLL patients as large centers
- Be informed about post-exposure treatment options
  - \*Paxlovid antiviral treatment
  - \*Remdesivir antiviral treatment
  - \*Sotrovimab monoclonal antibody treatment
  - Molnupiravir antiviral treatment
  - Convalescent plasma (antibodies from recovered Covid patients)
- Treatments are usually **more effective early** in the course of the disease
- If you don't have a true CLL expert on your team, establish care with one asap
- Therapeutic locator database: <https://healthdata.gov/Health/COVID-19-Public-Therapeutic-Locator/rxn6-qnx8/data>

